BladdEr Full OR Empty for Pelvic Radiation Therapy

Last updated: February 15, 2026
Sponsor: University of California, San Diego
Overall Status: Active - Recruiting

Phase

3

Condition

Pelvic Cancer

Treatment

Radiation therapy

Clinical Study ID

NCT06651697
811100
  • Ages > 18
  • All Genders

Study Summary

The present study evaluates empty and full bladder protocols for radiation therapy of genitourinary (GU), gynecological (Gyn), and gastrointestinal (GI) malignancies of the pelvis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Provision of signed and dated informed consent form

  • Stated willingness to comply with all study procedures and availability for theduration of the study

  • Persons, aged at least 18 years

  • Deemed eligible to undergo curative intent radiation therapy for primary GU, GI, orGyn malignancy of the pelvis.

  • For participants able to become pregnant: use of highly effective contraception forat least 1 month prior to screening and agreement to use such a method during studyparticipation

  • For participants able to cause a pregnancy: use of condoms or other methods toensure effective contraception with partner

Exclusion

Exclusion Criteria:

  • Pregnancy

  • Tumor invading the bladder, as judged by the enrolling physician based on availableclinical information

  • Contraindications to radiotherapy, including Crohn's disease and active connectivetissue disorders such as scleroderma or uncontrolled lupus

  • Prior radiation therapy to an area requiring treatment in the present study

Study Design

Total Participants: 300
Treatment Group(s): 1
Primary Treatment: Radiation therapy
Phase: 3
Study Start date:
November 19, 2024
Estimated Completion Date:
December 31, 2029

Study Description

Pelvic radiation therapy plays a key role in the treatment of common genitourinary (GU), gynecological (Gyn), and gastrointestinal (GI) malignancies of the pelvis. Prior to starting a course of radiation therapy, patients undergo a CT simulation that allows for computer-based optimization of radiation dose delivery to target while simultaneously minimizing dose to surrounding normal tissues, such as the bladder and rectum. Commonly, physicians instruct patients undergoing pelvic radiation therapy to present with a reproducibly full bladder for the simulation and for each subsequent treatment session with the hope that increased distance between normal tissues (anterior bladder wall and bowel) and treatment target will limit toxicity. However, treating with a full bladder can result in wide variations in bladder volume. Often patients are unable to reproduce the bladder distention achieved at simulation, especially as typical urinary symptoms related to radiation develop during treatment. As the initial CT simulation is used to calculate dose distribution, bladder volume changes can affect radiation dose distribution to the bladder itself as well as adjacent pelvic organs. Given the challenges and uncertainties of treating with a full bladder, there has been increasing interest in bladder empty protocols. Retrospective, non-randomized, single-institution studies demonstrate that bladder empty protocols reduced absolute variation in bladder volume during treatment, had minimal impact on treatment related toxicity, and had non-inferior biochemical progression free survival, GI toxicities, and GU toxicities. However, prospective data is very limited. The present study plans to fill this knowledge gap by randomizing study participants to empty and full bladder protocols for simulation and radiation therapy.

Connect with a study center

  • University of California, San Diego

    San Diego, California 92093
    United States

    Site Not Available

  • University of California, San Diego

    San Diego 5391811, California 5332921 92093
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.